Yahoo Suche Web Suche

Suchergebnisse

  1. Suchergebnisse:
  1. Barinthus Biotherapeutics plc (formerly Vaccitech plc) is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. [1] [2] Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus ...

  2. VACCITECH AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Vaccitech PLC (spons. ADRs) | A3CN5Q | BRNS | US91864C1071.

  3. 12. Apr. 2021 · Impfstoff. Das britische Biotechnologie-Start-up Vaccitech strebt einen Börsengang an der Nasdaq an. Das Unternehmen steht hinter dem COVID-19-Impfstoff des Pharmakonzerns AstraZeneca und peilt...

    • Benjamin Heimlich
  4. 11. Apr. 2021 · Vaccitech: Der Briten-Stolz bevorzugt für Börsenstart die USA. Vaccitech ist der ganze Stolz der Inselnation. Das Unternehmen hat gemeinsam mit der Universität Oxford und dem Pharmakonzern ...

  5. 21. Juni 2021 · Vaccitech is entering trials to treat lung and prostate cancer this year, while rivals BioNTech and Moderna have been developing cancer medicines using mRNA. They all hope to use the new ...

  6. 7. Apr. 2021 · Vaccitech, the start-up that owns crucial biotechnology behind the Oxford/AstraZeneca vaccine, has confidentially filed for an initial public offering in the US.

  7. 17. März 2021 · The Oxford start-up Vaccitech that owns the biotech platform behind the AstraZeneca Covid-19 vaccine has raised $168m, as it seeks to use similar technology to treat other infectious diseases and ...